ArticleCurrent organic synthesis2025
Design, Synthesis, and Biological Assessment of Bis-thiazole Derivatives as Promising Anticancer Agents with Molecular Docking Insights.
Article in Current organic synthesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Solvent-free synthesis of quinazolinone-chalcone hybrids and their evaluation as dual inhibitors of AChE and BuChE for alzheimer's disease.Die Naturwissenschaften · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThiazoles and bis-thiazoles are recognized for their anticancer and antitubercular properties, making them crucial in medicinal chemistry. This study focuses on synthesizing and evaluating novel bis-thiazole derivatives. MATERIALS AND
methodsBis-thiosemicarbazone derivative 3 was used as a precursor to synthesize bis-thiazole (6a-f, 12a-h) and bis-thiazolone (9a-d) derivatives through reactions with appropriate reagents. Anticancer activity was screened using the MTT assay on HCT-116 cells, while antitubercular activity was tested using the microplate Alamar blue assay (MABA). The derivatives were synthesized under optimized reflux conditions and characterized using spectroscopic techniques. Biological assays evaluated their therapeutic potential.
resultsThe compounds displayed variable cytotoxicity and antitubercular efficacy. Molecular docking studies on dihydrofolate reductase (DHFR) revealed significant interactions, suggesting potential mechanisms of action. DISCUSSION: The results highlight the influence of structural features on biological activity, with active compounds showing favorable interactions and docking scores.
conclusionBis-thiazole and bis-thiazolone derivatives exhibit promising anticancer and antitubercular potential, warranting further investigation for therapeutic applications.
Indexed as
Identifiers
41714916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.